title: Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3.
abstract: OBJECTIVE
  The treatment of ovarian tumors is carried out with platinum medicine which can lead to incompatibilities or resistances. Thus, it is of great interest to check new medicine suitability for its application. AZD1152 is an Aurora kinase inhibitor predominantly works against Aurora kinase B involved in the chromosome segregation. Cells become polyploidy and reduce the proliferation by this impairment. To investigate whether AZD1152, may play a role in the treatment of ovarian carcinoma we serving it to the cisplatinum-resistant cell line SKOV3 alone and in combination with platinum.
  
  
  METHODS
  We look at the proliferation, the ploidy, the phases of cell cycle and the apoptosis activity of the cells.
  
  
  CONCLUSIONS
  We could show that the combination of both medicines in the preclinical experiment produces a working advantage.
authors: Department of Gynecology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, People's Republic of China.
authors: Yaxi
authors: Y
authors: Ma
authors: Jörg
authors: J
authors: Weimer
authors: Regina
authors: R
authors: Fredrik
authors: Sabine
authors: S
authors: Adam-Klages
authors: Susanne
authors: S
authors: Sebens
authors: Amke
authors: A
authors: Caliebe
authors: Felix
authors: F
authors: Hilpert
authors: Christel
authors: C
authors: Eckmann-Scholz
authors: Norbert
authors: N
authors: Arnold
authors: Christian
authors: C
authors: Schem
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D064107:Aurora Kinase B / Q000037:antagonists & inhibitors; D016190:Carboplatin / Q000494:pharmacology*; D002277:Carcinoma / Q000188:drug therapy*; D053148:Caspase 3 / Q000378:metabolism; D053179:Caspase 7 / Q000378:metabolism; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D004357:Drug Synergism; D005260:Female; D006801:Humans; D010755:Organophosphates / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011123:Polyploidy; D011799:Quinazolines / Q000494:pharmacology*
chemical_list: C520647:2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate; D000970:Antineoplastic Agents; D010755:Organophosphates; D011799:Quinazolines; D016190:Carboplatin; D064107:Aurora Kinase B; D053148:Caspase 3; D053179:Caspase 7; D002945:Cisplatin